Why quantum will not scale without diagnostics

What if the real bottleneck in quantum is not building the chip, but learning why it fails?In this episode, I unpack the key learnings from Part 2 of my deep dive with Johannes Jobst, CEO of QuantaMap. One of my biggest takeaways is that quantum may need its own process control and diagnostics layer before the industry can truly scale. Building a few quantum chips in a lab is one thing. Building thousands of high quality chips with repeatable performance and acceptable yield is something very different.This episode is for investors, founders, and anyone trying to understand what it will take for quantum to move from lab to fab. In semiconductors, scaling did not happen through transistor innovation alone. It also required decades of progress in inspection, metrology, yield learning, process control, and manufacturing feedback loops. Quantum is only beginning that journey.That is what makes this conversation so important. If yield remains low and failure analysis stays slow, scaling becomes much harder. Without a real diagnostics layer, every failed chip stays a mystery instead of becoming a learning cycle. The companies that help the industry learn, improve, and manufacture quantum chips reliably at scale may end up becoming one of the most important layers in the value chain.💡 In this episode, we cover:Why diagnostics may be a critical missing layer in quantum manufacturingWhy quantum scaling needs more than better qubitsHow cryogenic inspection changes what chipmakers can actually learnWhy room-temperature measurements often miss the real problemHow process control, yield learning, and feedback loops could shape quantum manufacturingWhy “business as usual” is still one of the biggest bottlenecks in the marketHow QuantaMap thinks about becoming a deeply embedded diagnostics layerWhat investors should watch as quantum moves from lab to fabChapters 00:00 Why chip diagnostics matters in quantum00:44 How QuantaMap’s cryogenic measurement works 04:27 Why multimodal imaging matters 06:15 Why process control comes later 08:09 Why cryogenic scanning matters 15:29 Business as usual is the real competition 20:42 Barriers to entry and customer lock-in 23:44 The ASML-style ambition 28:57 Diagnostics as a service and tool sales 34:44 Why timing from lab to fab matters 46:53 What would increase conviction 51:13 Why QuantaMap matters in the value chain🔗 Resources / Links 🎧 Listen to all episodes →https://open.spotify.com/show/7HZpSCz1w7a782e1B26MYA?si=JjJ7gTAfRGaZwnYwMa65mQShare this episode with someone investing in or building in quantum, and make sure to subscribe or follow Beyond the Qubit for more conversations on quantum technology, markets, and investing.📌 Disclaimers: This is not investment advice. I do this under my personal name and do not represent any company.